Sinopharm Group Co (SHTDY)
OTHER OTC:SHTDY
Want to see SHTDY full AI Analyst Report?
Top Page
Sinopharm Group Co
(OTC:SHTDY)
Select Model
Select Model
Rating:60Neutral
Price Target:
$13.00
▼(-0.99% Downside)
Action:Downgraded
Date:04/26/26
The score is supported mainly by attractive valuation (very low P/E and a ~3.86% dividend yield). This is tempered by weakening financial performance (softening revenue, margin compression, and higher leverage) and bearish technical momentum (price below key moving averages with negative MACD and weak RSI).
Positive Factors
Nationwide logistics & sales network
A nationwide logistics and sales network is a durable competitive asset in healthcare distribution. It lowers fulfillment costs, supports reliable delivery for hospitals and pharmacies, and creates switching costs for customers and suppliers, sustaining revenue and tender competitiveness over months.
Negative Factors
Rising leverage
A meaningful rise in leverage reduces financial flexibility and raises interest-cost sensitivity. For a low-margin distributor, higher debt amplifies earnings volatility, constrains capital allocation for logistics/technology upgrades, and increases risk during weaker demand periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Nationwide logistics & sales network
A nationwide logistics and sales network is a durable competitive asset in healthcare distribution. It lowers fulfillment costs, supports reliable delivery for hospitals and pharmacies, and creates switching costs for customers and suppliers, sustaining revenue and tender competitiveness over months.
Read all positive factors
Sinopharm Group Co (SHTDY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.98B
Dividend Yield3.75%
Average Volume (3M)1.38K
Price to Earnings (P/E)3.7
Beta (1Y)0.19
Revenue Growth-1.48%
EPS Growth1.66%
CountryUS
Employees108,217
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)11.35
Shares Outstanding268,362,150
10 Day Avg. Volume773
30 Day Avg. Volume1,375
Financial Highlights & Ratios
PEG Ratio-4.39
Price to Book (P/B)0.64
Price to Sales (P/S)0.10
P/FCF Ratio4.32
Enterprise Value/Market Cap13.63
Enterprise Value/Revenue0.17
Enterprise Value/Gross Profit2.29
Enterprise Value/Ebitda4.53
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sinopharm Group Co Business Overview & Revenue Model
Company Description
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutic...
How the Company Makes Money
Sinopharm makes money mainly by distributing and selling pharmaceuticals and healthcare products across China. Its core revenue stream is pharmaceutical distribution (wholesale), where it purchases drugs and other medical products from manufacture...
Sinopharm Group Co Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
52
Neutral
Cash Flow
60
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 559.50B | 584.51B | 596.57B | 552.15B | 521.05B |
| Gross Profit | 40.09B | 44.26B | 48.51B | 47.43B | 44.05B |
| EBITDA | 20.38B | 20.17B | 26.90B | 26.25B | 24.68B |
| Net Income | 6.96B | 7.05B | 9.05B | 8.53B | 7.76B |
Balance Sheet | |||||
| Total Assets | 390.61B | 392.83B | 383.39B | 364.78B | 335.41B |
| Cash, Cash Equivalents and Short-Term Investments | 61.60B | 54.31B | 63.81B | 55.22B | 43.54B |
| Total Debt | 108.65B | 76.39B | 73.78B | 69.59B | 68.37B |
| Total Liabilities | 256.36B | 266.14B | 263.08B | 254.71B | 235.76B |
| Stockholders Equity | 84.01B | 78.88B | 74.58B | 68.07B | 61.89B |
Cash Flow | |||||
| Free Cash Flow | 12.52B | 9.58B | 14.84B | 18.55B | 7.05B |
| Operating Cash Flow | 14.14B | 11.55B | 17.17B | 20.96B | 9.31B |
| Investing Cash Flow | -963.89M | -3.75B | -944.53M | -3.59B | -1.27B |
| Financing Cash Flow | -18.69B | -17.29B | -7.64B | -5.69B | -14.69B |
Sinopharm Group Co Technical Analysis
Negative
13.13
Price Trends
12.66
Negative
12.98
Negative
12.71
Negative
Market Momentum
-0.39
Positive
27.57
Positive
4.40
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SHTDY, the sentiment is Negative. The current price of 13.13 is above the 20-day moving average (MA) of 11.84, above the 50-day MA of 12.66, and above the 200-day MA of 12.71, indicating a bearish trend. The MACD of -0.39 indicates Positive momentum. The RSI at 27.57 is Positive, neither overbought nor oversold. The STOCH value of 4.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SHTDY.
Sinopharm Group Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $93.27B | 22.46 | -265.44% | 0.37% | 12.36% | 48.80% | |
64 Neutral | $2.21B | 15.09 | 10.29% | ― | -4.31% | -8.94% | |
63 Neutral | $46.79B | 31.11 | -55.72% | 0.98% | 12.80% | 2.04% | |
60 Neutral | $6.98B | 3.74 | 8.62% | 3.75% | -1.48% | 1.66% | |
59 Neutral | $50.95B | 9.31 | 115.93% | 0.66% | 5.95% | 51.04% | |
56 Neutral | $8.28B | 19.36 | 11.86% | ― | 5.64% | 2.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SHTDY
Sinopharm Group Co
11.32
-0.10
-0.90%
COR
Cencora
264.75
-24.43
-8.45%
CAH
Cardinal Health
199.23
47.63
31.42%
HSIC
Henry Schein
73.23
1.15
1.60%
MCK
McKesson
754.68
38.78
5.42%
PBH
Prestige Consumer Healthcare
47.19
-37.23
-44.10%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.